Streetbeat News

Products Services

AAL

DAL

JBLU

UAL

Delta Air Lines (NYSE:DAL) reported its highest ever quarterly earnings and raised its full year profit outlook due to strong international travel demand and lower fuel costs. Despite high inflation, consumers are prioritizing travel, maintaining the post-pandemic travel boom. Delta's total revenue per seat mile was up 1% YoY in Q2, with a 17% jump in capacity. United Airlines (NASDAQ:UAL) unveiled its first new seat in nearly a decade for premium passengers. American Airlines (NASDAQ:AAL) and JetBlue Airways (NASDAQ:JBLU) are also mentioned in the context of the industry trend.

Portfolio Pulse from Upwallstreet

July 14, 2023 | 2:18 pm

RNLSY

STLA

TSLA

WKSP

Renault (OTC:RNLSY) Chairman expressed concerns about Europe's over-reliance on China for EV supply chain, following China's decision to restrict metal exports. In the US, Worksport Ltd (NASDAQ:WKSP) announced significant progress at its US facility, aiming to deliver its Solis solar-powered tonneau cover and COR remote power storage system. Tesla Inc (NASDAQ:TSLA) stated that the US could go all-electric by the end of the decade. Toyota Motor (NYSE:TM) and Stellantis (NYSE:STLA) believe the EPA's expectations for EV market growth are overly optimistic. General Motors (NYSE:GM) aims to surpass Tesla in EV sales in the US.

Portfolio Pulse from Upwallstreet

July 14, 2023 | 2:13 pm

BLK

ERIC

JPM

META

MSFT

NOK

NVO

UNH

WFC

Hollywood studios propose using AI replicas of actors. Meta Platforms' Threads app sees a decline in engagement. Citigroup, UnitedHealth, Wells Fargo, JPMorgan Chase, and BlackRock deliver strong Q2 earnings. Nokia and Ericsson shares drop after Q2 earnings. Roivant Sciences in talks with Roche for a potential $7B drug deal. WHO labels aspartame as a possible carcinogen. Microsoft and Activision Blizzard consider UK rights divestiture to appease regulators. Nissan plans to invest in Renault's EV unit. Novo Nordisk's weight-loss drug to be launched in Germany.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 2:09 pm

NVO

Novo Nordisk's weight-loss medication, Wegovy, will be priced at €301.91 for a four-week course in Germany. The drug will be launched in Germany by the end of this month. The company has urged doctors to restrict prescriptions to medically necessary cases. Challenges in production and high demand in the US have resulted in a slower European rollout of Wegovy than anticipated. Novo Nordisk has also filed lawsuits against three pharmacies for illegally selling products claiming to contain semaglutide, the active ingredient in its weight loss and diabetes drugs.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 1:40 pm

NTRB

NTRBW

Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) has increased its existing credit line to $5 million to support the continued development and regulatory submission process for its patented lead product platform, AVERSA™ Fentanyl. The company is targeting FDA submission for AVERSA™ Fentanyl in the first half of 2024. AVERSA™ Fentanyl, which combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva Drug Delivery’s FDA-approved transdermal fentanyl patch system, is estimated to reach peak annual US sales of $80M - $200M.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:21 pm

CJET

Chijet Motor Company, Inc. (NASDAQ:CJET) announced that its majority-owned subsidiary FAW Jilin Automobile Co., Ltd. has completed its first shipment of automobile orders to Peru through its newly developed export operation at Tianjin Port, China. This marks the official opening of FAW Jilin's dual-channel export model, indicating a new phase of development for the company's international marketing business.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:20 pm

THRX

Theseus Pharmaceuticals Inc (NASDAQ:THRX) has decided to terminate the development of THE-630 for gastrointestinal stromal tumors (GIST) due to dose-limiting toxicities. The company will discontinue enrollment in the ongoing phase 1/2 study. The decision was made after observing hand-foot skin reactions in patients. The company is now prioritizing THE-349 for EGFR mutant non-small cell lung cancer and announced a new program targeting KIT for patients with early-line GIST. Following the news, THRX shares are down 65.50%.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 1:19 pm

CVM

CEL-SCI Corporation (NYSE:CVM) has concluded a meeting with the U.S. FDA regarding the approval of Multikine for the treatment of head and neck cancer. The FDA acknowledged the need for improved treatments and is open to collaboration with CEL-SCI. The company is also pursuing approval in Europe, the UK, and Canada, with commercialization possibly beginning in 2024 if Health Canada approves the submission. CEL-SCI's CEO highlighted the drug's potential benefits, including a 4-year median survival benefit and complete tumor elimination in some patients within 3 weeks.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:15 pm

LAES

WKEY

WISeKey International Holding Ltd. (NASDAQ:WKEY) and its subsidiaries, SEALSQ Corp (NASDAQ:LAES) and WISeSat AG, are developing an ultra-secure picosatellite solution for Quantum-Ready IoT communications. The new generation of WISeSat-ready satellites will incorporate post-quantum solutions, with microchips and devices designed to withstand the evolution of computational power. Seventeen WISeSat-ready satellites have already been launched into orbit with SpaceX as part of an 80-satellite constellation.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:13 pm